Aurinia EVP Research and CMO depart effective Oct 31, 2022

Aurinia Pharmaceuticals Inc.

Robert Huizinga, EVP Research, and Neil Solomons, CMO, mutually agreed to leave Aurinia.
Huizinga severance: $575,015 base pay, $159,311 vacation, $191,672 bonus target (50% of 2022).
Solomons severance: $698,230 base pay, $192,157 vacation, $232,743 bonus target (50% of 2022).
Both departures effective Oct 31, 2022; benefits coverage for up to 18 months.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Huizinga

Executive Vice President, Research

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2022-10-31
Filed: October 21, 2022, 7:59 PM ET

On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.

Departed

Neil Solomons

Chief Medical Officer

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2022-10-31
Filed: October 21, 2022, 7:59 PM ET

On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Huizinga resigned as Executive Vice President, Research at Aurinia Pharmaceuticals Inc..

Action: resigned
Role: Executive Vice President, Research

Exact text from the filing

On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Solomons resigned as Chief Medical Officer at Aurinia Pharmaceuticals Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-026779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.